51st week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170360742 | Formulations For Cathepsin K Inhibitors - The instant invention relates to pharmaceutical compositions containing cathespin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions. | 2017-12-21 |
20170360743 | BIFLAVONE COMPOUND AND USES THEREOF FOR TREATING CANCERS AND PREPARING DRUGS - Provided in the present invention is a compound having these structure of formula I or a pharmaceutically acceptable salt thereof. Also provided in the present invention is a pharmaceutical composition containing the compound, and a use of the compound for treating cancers. | 2017-12-21 |
20170360744 | AGENT CONTAINING FLAVONOID DERIVATIVES FOR TREATING CANCER AND INFLAMMATION - A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions. | 2017-12-21 |
20170360745 | CANNABIS EXTRACTS AND METHODS OF PREPARING AND USING SAME - The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from | 2017-12-21 |
20170360746 | POLYMORPH OF GRANATICIN B - The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof. | 2017-12-21 |
20170360747 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS - The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment. | 2017-12-21 |
20170360748 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF - The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative disease, an autoimmune or inflammatory disorder, a neurodegenerative disease, or a combination thereof, also are disclosed. | 2017-12-21 |
20170360749 | METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION - A pharmaceutical composition for aerosol administration and method of preventing or treating a pulmonary disease or condition in a subject with a SphK1 inhibitor are provided. | 2017-12-21 |
20170360750 | SUNITINIB FORMULATIONS AND METHODS FOR USE THEREOF IN TREATMENT OF GLAUCOMA - Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or other inhibitors of JNK signaling, which bind to DLK. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or reduce neuronal death due to elevated intraocular pressure. Upon administration, the sunitinib or other inhibitor is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity, and which provide much longer release than inhibitor without conjugate. | 2017-12-21 |
20170360751 | Methods and Compositions for the Treatment of Retinopathy and Other Ocular Diseases - Compositions and methods for the treatment of ocular diseases are disclosed. | 2017-12-21 |
20170360752 | ANTIVIRAL AGENTS DIRECTED AGAINST RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus. | 2017-12-21 |
20170360753 | ORGANIC COMPOUNDS - The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders. | 2017-12-21 |
20170360754 | ANTICANCER COMPOSITIONS - The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent. | 2017-12-21 |
20170360755 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION - A method of treating disorders associated with NO/SNO deficiency or benefiting from increased SNO in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, SNO-CoAR inhibitor, and/or SNO-CoA at an amount(s) effective to promote S-nitrosylation of proteins in the subject. | 2017-12-21 |
20170360756 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS - The present application relates to substituted heterocycles compound of Formula I and pharmaceutical compositions thereof useful for the inhibition of BET protein function by binding to bromodomains (Formula I). | 2017-12-21 |
20170360757 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS - The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC). | 2017-12-21 |
20170360758 | COMPOSITION FOR EXTERMINATING SCUTICOCILIATES IN FISH INCLUDING MEBENDAZOLE - The present disclosure relates to a composition for exterminating scuticociliates in fish, comprising Mebendazole as an active ingredient, and to a method for exterminating scuticociliates by performing oral administration or immersion administration of Mebendazole in fish. According to the present disclosure, the composition and the extermination method have excellent effects in exterminating scuticociliates in fish, and can be efficiently used in the aquaculture industry by performing oral administration or immersion administration. | 2017-12-21 |
20170360759 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS - The present invention provides compounds of Formula (I): | 2017-12-21 |
20170360760 | Inhibitors of Bromodomains - The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors. | 2017-12-21 |
20170360761 | Selective Inhibition of HDAC6 and HDAC8, and Methods of Use Thereof - The present invention relates to methods of selectively modulating (for example inhibiting) the activity of histone deacetylase 6 and/or 8 (HDAC6 and/or HDAC8), and treating HDAC6 and/or HDAC8 associated diseases, including, for example, cancers, inflammatory disorders, and neurodegenerative disorders. | 2017-12-21 |
20170360762 | COMBINATION OF IBUDILAST AND RILUZOLE AND METHODS OF USING SAME - The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof. | 2017-12-21 |
20170360763 | METHODS OF USE OF CYCLOPAMINE ANALOGS - The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: | 2017-12-21 |
20170360764 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE - This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a pharmaceutical composition for the treatment of cartilage disease which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of cartilage disease in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. | 2017-12-21 |
20170360765 | SUBSTITUTED PYRIDINES AS BROMODOMAiN INHIBITORS - The disclosure relates to substituted pyridines, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy. | 2017-12-21 |
20170360766 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS - Described are a group of isoxazol-3(2H)-one analogues and their use in topical formulations for the treatment and prophylaxis of dermatological disorders. | 2017-12-21 |
20170360767 | MULTI-LAYER NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION - The invention provides a multi-layered pharmaceutical composition comprising two or more formulations with varying properties. In some embodiments, the pharmaceutical compositions provide combinations of different organoleptic properties within the same product. In certain embodiment, these combinations allow for a modified release profile of active ingredients as the user enjoys the pharmaceutical composition. The invention further provides methods for making and using the pharmaceutical composition. | 2017-12-21 |
20170360768 | Novel Regimens of Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects - Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of | 2017-12-21 |
20170360769 | INJECTABLE ANTICANCER COMPOSITION FOR LOCAL ADMINISTRATION CONTAINING SUSPENSION OF QUININE SALT - Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an IC | 2017-12-21 |
20170360770 | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-HLA-DR antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The methods and compositions are particularly useful for treating AML, ALL or multiple myeloma. | 2017-12-21 |
20170360771 | TREATING POSTOPERATIVE NAUSEA AND VOMITING - Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonists, dopamine receptor agonists, MAO inhibitors, serotonin receptor agonists, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin releasing agents, serotonin-norepinephrine-dopamine reuptake inhibitors, opioids, or analgesics. | 2017-12-21 |
20170360772 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2017-12-21 |
20170360773 | COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2017-12-21 |
20170360774 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2017-12-21 |
20170360775 | GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS - Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided. | 2017-12-21 |
20170360776 | COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2017-12-21 |
20170360777 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HT | 2017-12-21 |
20170360778 | Methods for Treating a Cytomegalovirus Infection - The present disclosure provides a method for inhibiting cytomegalovirus (CMV) replication in a cell infected with CMV, the method comprising contacting the cell with a bisbenzimidazole compound. The present disclosure provides a method of treating a CMV infection in an individual, the method comprising administering to the individual an effective amount of a bisbenzimidazole compound. | 2017-12-21 |
20170360779 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT - [Problem] Provided is a pharmaceutical composition for treating lung cancer in which mitochondrial Complex I is involved, particularly non-small cell lung cancer. | 2017-12-21 |
20170360780 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT - [Problem] Provided is a pharmaceutical composition for treating multiple myeloma. | 2017-12-21 |
20170360781 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT - [Problem] Provided is a pharmaceutical composition for treating various types of cancer in which mitochondrial Complex I is involved, particularly colorectal cancer, leukemia and/or malignant lymphoma. | 2017-12-21 |
20170360782 | PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA - A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α | 2017-12-21 |
20170360783 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 2017-12-21 |
20170360784 | TRIZOL-1-OL ANALOGS ANTI-RETROVIRAL LATENCY DRUGS - In one aspect, the invention relates to triazol-1-ol compounds, analogs thereof, compositions comprising same, and methods of using same, alone or in combination with other agents, to reactivate latent retroviruses, and more particularly to reactivate latent HIV-1. Such compounds, compositions, and methods can be used, for example, in connection with diagnosing and/or treating a retrovirus, and more specifically HIV-1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2017-12-21 |
20170360785 | PYRIMIDINE FGFR4 INHIBITORS - Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same. | 2017-12-21 |
20170360786 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2017-12-21 |
20170360787 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD - The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of AP levels via selective modulation (e.g., inhibition) of γ-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a compound that results in the modulation of γ-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain AP disorder, such as Alzheimer's disease. | 2017-12-21 |
20170360788 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K - This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases. | 2017-12-21 |
20170360789 | FAS Inhibitors and Methods Associated Therewith - The present invention relates to compounds, compositions and methods comprising nanoparticles (NP) that are based on hyaluronic acid (HLA) that have been modified with hydrophobic moieties that can entrap FASN inhibitor compounds. In one embodiment, the FASN inhibitor compounds include Orlistat. In one embodiment, the hydrophobic moieties comprise 5-βCA, Pba, or ODA, or combinations thereof. In a variation, the present invention relates to a composition comprising NPs based upon HLA, Orlistat, one or more of the hydrophobic moieties comprising 5-βCA, Pba, or ODA, and one or more of members selected from the group consisting of PEG and a dilute solution containing SDS. | 2017-12-21 |
20170360790 | KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER - Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents. | 2017-12-21 |
20170360791 | PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE BIOAVAILABILITY OF POORLY SOLUBLE DRUGS - Pharmaceutical compositions comprising poorly soluble compounds, such as BCS class II or class IV drugs (e.g. amuvatinib), are provided. The pharmaceutical compositions are effective for increasing the bioavailability of the compounds. Related kits and methods are also provided. | 2017-12-21 |
20170360792 | ORGANIC COMPOUNDS - The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders. | 2017-12-21 |
20170360793 | USE OF ANAGRELIDE FOR TREATING CANCER - The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis. | 2017-12-21 |
20170360794 | JAK INHIBITOR - The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK. | 2017-12-21 |
20170360795 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS - Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders. | 2017-12-21 |
20170360796 | BTK INHIBITOR COMBINATIONS AND DOSING REGIMEN - Disclosed herein are methods and combination dosing regimen of administering a combination of a BTK inhibitor (e.g. ibrutinib) and an anti-CD20 therapeutic agent for the treatment of a hematologic malignancy. In one aspect is a combination dosing regimen for the treatment of a hematologic malignancy in a subject in need thereof comprising a first phase and a second phase, wherein the first phase is an administration of a BTK inhibitor as a single-agent treatment for a first extended period of time, and the second phase is an administration of a combination of the BTK inhibitor and an anti-CD20 therapeutic agent for a second extended period of time. In one embodiment, the first extended period of time is a period of up to 90 days. | 2017-12-21 |
20170360797 | METHOD FOR TREATING CANCER - The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s). | 2017-12-21 |
20170360798 | ANAVEX2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION - This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use. | 2017-12-21 |
20170360799 | AQUEOUS COMPOSITION - A technique is provided for suppressing the crystal precipitation of an aqueous composition containing a halogenated isoquinoline derivative during low-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): | 2017-12-21 |
20170360800 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES - The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N═; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. | 2017-12-21 |
20170360801 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY - Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor. Also disclosed is a method for treating cancer in a subject, comprising co-administering to the subject a bromodomain inhibitor and an immunostimulatory agent. | 2017-12-21 |
20170360802 | Enrichment Method of Ergosterol Peroxide from Sporoderm-Broken Ganoderma Lucidum Spore Powder - The invention provides an enrichment method of Ergosterol peroxide from sporoderm-broken | 2017-12-21 |
20170360803 | METHODS FOR TREATING OR PREVENTING CANCER IN A KRAS-VARIANT PATIENT AND FOR DIAGNOSING RISK OF DEVELOPING MULTIPLE PRIMARY BREAST TUMORS - The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject. | 2017-12-21 |
20170360804 | C-19 Steroids for Inhibiting Neovascularization - The present invention relates to the field of medicine, particularly to novel uses of C-19 steroid compounds having an androsten-17-(OR | 2017-12-21 |
20170360805 | MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT - Disclosed herein are methods and compounds for treating a motor-associated neurodegenerative disease or condition. In some instances, also included herein are methods and compounds for treating a TDP-43 associated neurodegenerative disease or condition (e.g., ALS and frontotemporal dementia) and/or a C9orf72 associated neurodegenerative disease or condition (e.g., ALS and frontotemporal dementia). | 2017-12-21 |
20170360806 | CORTEXOLONE 17ALPHA-BENZOATE FOR USE IN THE TREATMENT OF TUMOURS - The present invention provides certain cortexolone derivatives of formula (I), and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products. | 2017-12-21 |
20170360807 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY - The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. | 2017-12-21 |
20170360808 | TOPICAL FORMULATIONS COMPRISING A STEROID - The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders. | 2017-12-21 |
20170360809 | VASCULAR CALCIFICATION - The invention relates to the use of a poly(ADP ribose) polymerase (PARP) inhibitor and/or a tetracycline, for treating, preventing or ameliorating medial vascular calcification, and to pharmaceutical compositions comprising PARP inhibitors or tetracycline. | 2017-12-21 |
20170360810 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE - Use of a derivative attaining C-O-P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent. | 2017-12-21 |
20170360811 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME - The novel bisphosphonic acid ester derivatives represented by the following formula (1): | 2017-12-21 |
20170360812 | PHOSPHOLIPID PREPARATIONS FOR THE IMPROVEMENT OF COMMUNICATION SKILLS - The preparation of the present invention was found to be effective for the majority of patients diagnosed with autism. In patients characterized by delayed language development and non-expressive/non-emotional communication patterns, the preparation of the invention was found to be more effective than in patients that were diagnosed with autism without delayed language development and with expressive/emotional communication patterns, even though all patients consumed the preparation for a similar duration. Specific analysis for the type and quality of the improvement detected within the group of patients characterized by delayed language development and non-expressive/non-emotional communication patterns revealed that the majority of patients improved in various communication abilities: speech, language, conversation, and social play. | 2017-12-21 |
20170360813 | COMPOSITIONS AND METHODS FOR TREATING MEDULLOBLASTOMA - Provided are methods and compositions for treating an individual who has a medulloblastoma. Methods for treating an individual who has a medulloblastoma tumor can include a step of administering to the individual, at a dose sufficient to reduce the size and/or growth rate of the medulloblastoma tumor, a composition that includes a casein kinase II (CK2) inhibitor (e.g., a CK2-selective inhibitor such as CX-4945). In some cases, the medulloblastoma tumor is a hedgehog-dependent medulloblastoma tumor. In some cases, the medulloblastoma tumor is a hedgehog-independent medulloblastoma tumor. In some cases, the medulloblastoma tumor is smoothened inhibitor-resistant (SMO inhibitor-resistant). In some cases, the medulloblastoma is resistant to treatment with 4,5,6,7-tetrabromo-2H-benzotriazole (TBB). In some cases, the dose is sufficient to cause long term regression of the medulloblastoma tumor, and in some cases, the dose is sufficient to increase the chance of survival of the individual. | 2017-12-21 |
20170360814 | Pain Reliever Composition - An inventive composition including an amount of sugar or sugar alcohol, an amount of alkalizing agent, and an amount of vehicle; whereby the inventive composition is formulated for transdermal administration to alleviate one or more disorder symptoms, for example neurogenic pain, or to treat one or more disorders, for example neurogenic inflammation. | 2017-12-21 |
20170360815 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST AIRBORNE PATHOGENS AND IRRITANTS - The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation or ingestion of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses. | 2017-12-21 |
20170360816 | METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS - Provided herein are methods for treating a pulmonary infection in a patient in need thereof for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period. | 2017-12-21 |
20170360817 | USE OF AMINOGLYCOSIDE ANALOGS IN THE TREATMENT OF RETT SYNDROME - Compounds, methods and uses of pseudo-trisaccharide aminoglycosides represented by the general formula I: | 2017-12-21 |
20170360818 | METHODS OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period. | 2017-12-21 |
20170360819 | PROCESS FOR PRODUCING A PARTICULATE COMPOSITION COMPRISING AN HYDROUS CRYSTALLINE 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside. | 2017-12-21 |
20170360820 | METHODS AND COMPOSITIONS FOR TREATING EUKARYOTIC INFECTIONS VIA ALTERING AGGREGATION DYNAMICS OF RAPTOR/KOG1 - Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or other agents, and said agents may be used to treat or prevent a disease or condition associated with the fungi and parasite. The agent may target Kog1 of TORC1, e.g., the agent may directly or indirectly inhibit Kog1 leading to aggregation of the TORC1 complex. | 2017-12-21 |
20170360821 | TREATMENT AND PREVENTION OF THROMBOSIS USING AN ANTI-MIR - Disclosed are anti-miR compositions and methods of use of the same for treatment of or reducing the occurrence of thrombosis and thrombosis related diseases and disorders by reducing platelet activation. | 2017-12-21 |
20170360822 | MALODOR NEUTRALIZING COMPOSITION - A composition suitable for treating a variety of medical, aesthetic and cosmetic conditions in mucous membranes and occluded skin areas, comprising hyaluronic acid, N-acetylcysteine, an active agent and set to pH of less than 6, which is characterized by high in vivo stability, is disclosed, as well as uses thereof in temporally extended delivery of active agent to mucous membrane in bodily sites. | 2017-12-21 |
20170360823 | NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES - The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process. | 2017-12-21 |
20170360824 | SKIN COMPOSITIONS AND METHODS OF USE THEREOF - Provided are body corrective cosmetic formulations and methods of use thereof. | 2017-12-21 |
20170360825 | Composition and Kits for Inhibition of Pathogenic Microbial Infection and Methods of Using the Same - Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of a polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent. | 2017-12-21 |
20170360826 | METHODS FOR TREATING ALCOHOL WITHDRAWAL - This disclosure includes a method for treating a patient suffering from alcohol withdrawal. The method comprises administering an effective amount of oxygen to the patient and administering an effective amount of nitrous oxide to the patient. In some embodiments, the effective amount of oxygen and the effective amount of nitrous oxide are administered to the patient via a nitrous oxide sedation system. | 2017-12-21 |
20170360827 | Pharmaceutical Use of Potassium Hydroxide - This relates to the pharmaceutical use of KOH, in forms of topical, oral drugs or intravenous drip, prepared for treating high blood uric acid, especially gout. The external application refers to footbath in soaking solution or embrocation on attack position. The action of the drugs is also to promote the excretion of uric acid. Compared with colchicine and other drugs, KOH has three notable features. First, it takes effect quickly. No matter being applied by footbath, oral or embrocation, it can relieve symptoms within ten minutes, and the pain during gout attack will be significantly reduced. Second, it takes curative effect quickly. After application of the drugs for 2-3 consecutive days, gout symptoms will completely disappear. Third, it has no side effects. In one respect, with a low concentration, the KOH will not corrode the skin. In a further respect, potassium ion itself is diuretic and it has no harm to kidney. | 2017-12-21 |
20170360828 | Treatment of Rheumatoid Arthritis Using Noble Gas Mixtures - The invention disclosed provides means of inhibiting, ameliorating, and/or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity. | 2017-12-21 |
20170360829 | TREATMENT OF VASCULAR ANOMALIES - The present invention provides a novel approach to the diagnosis, treatment and management of vascular anomalies by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations associated with vascular anomalies, by modulation of the Renin-Angiotensin System expressed by the stem cells. | 2017-12-21 |
20170360830 | ANIMAL FEED SUPPLEMENT AND METHOD - A premix is disclosed. The premix includes a nitrate compound and salts thereof in the amount of greater than about 50% by weight of the premix. The premix also includes vitamins and trace minerals. The premix is formulated for use in at least one of a gestation or lactation phase of an animal and in an amount of less than about five percent by weight (5.0 wt %) inclusion per metric ton of the premix. A supplement for an animal feed for feeding during at least one of an animal's gestation phase and/or lactation phase is also disclosed. A method for feeding an animal is also disclosed. | 2017-12-21 |
20170360831 | Non-nasal treatment methods using carbon dioxide and saline - A method of treatment for mixed carbon dioxide, carbonic acid, saline and optional active additives for treating non-nasal ailments includes delivery of dosage of the treatment at specified flow rates, using a) main housing having a hollow central area containing the dosage; b) a dosage dispenser head located at the distal end of the main housing, and having at least one flow channel for movement of the dosage from the main housing through the dosage dispenser head and to external of the dosage dispenser head; c) a dosage release control component located between the main housing and the dosage dispenser head to permit flow of the dosage through the dosage dispenser head in response to increased pressure against the dosage; and d) a pressure-changing moveable component on the main housing. | 2017-12-21 |
20170360832 | HYPOCHLOROUS ACID FORMULATIONS AND METHODS FOR TREATING SKIN CONDITIONS - The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others. | 2017-12-21 |
20170360833 | METHOD FOR INDUCING CELL REPROGRAMMING, AND METHOD FOR PRODUCING PLURIPOTENT CELLS - An object of the present invention is to provide a pluripotent cell having high safety in application to regenerative medicine, and a method for production thereof. Another object of the present invention is to provide a pluripotent cell, particularly, having less concern for safety, such as a problem of cancerization of a cell, and the presence of bacteria in a cell, and a method for production thereof. According to the present invention, there is provided a method for producing a pluripotent cell from a somatic cell. The method comprises a step of inducing reprogramming of a somatic cell, by contacting the cell with a ribosome fraction derived from an organism. Further, according to the present invention, there is provided a composition for inducing reprogramming of a cell, comprising a ribosome fraction derived from an organism. | 2017-12-21 |
20170360834 | MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES - The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes. | 2017-12-21 |
20170360835 | USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS - A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. | 2017-12-21 |
20170360836 | COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT - Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents. | 2017-12-21 |
20170360837 | MATERIALS AND METHODS FOR TREATING ENDOTHELIAL DYSFUNCTION AND METHODS FOR MONITORING EFFICACY OF THERAPY IN A SUBJECT - The present disclosure is directed to materials and methods for treating endothelial dysfunction in a subject in need thereof. Methods of determining efficacy of treatment are also provided. | 2017-12-21 |
20170360838 | FACTORS AND CELLS THAT PROVIDE FOR INDUCTION OF BONE, BONE MARROW, AND CARTILAGE - Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo. | 2017-12-21 |
20170360839 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A PULMONARY DISORDER COMPRISING MESENCHYMAL STEM CELLS HAVING IMPROVED PROLIFERATION AND DIFFERENTIATION CAPACITY - A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema. | 2017-12-21 |
20170360840 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY - Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction. | 2017-12-21 |
20170360841 | METHODS FOR PRODUCING DOPAMINERGIC NEURONS AND USES THEREOF - The present application relates to a stem cell, a precursor or progenitor cell in which Plexin C1 has been inactivated, a dopaminergic (DA) neuron in which Plexin C1 has been inactivated, methods of preparing same and uses thereof for the treatment of Parkinson's disease. | 2017-12-21 |